Detalhe da pesquisa
1.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35658005
2.
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 990-1000, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35767205
3.
High Mortality After Total Knee Arthroplasty Periprosthetic Joint Infection is Related to Preoperative Morbidity and the Disease Process but Not Treatment.
J Arthroplasty
; 37(7): 1383-1389, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35314288
4.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Cancer
; 125(4): 533-540, 2019 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30570744
5.
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Invest New Drugs
; 37(3): 591, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30903344
6.
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Br J Haematol
; 178(3): 434-441, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28440559
7.
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
N Engl J Med
; 364(6): 501-13, 2011 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-21306237
8.
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Lung Cancer
; 190: 107512, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38417277
9.
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Invest New Drugs
; 31(6): 1487-98, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-23963796
10.
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Invest New Drugs
; 31(5): 1265-74, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23269537
11.
Therapy-induced malignant neoplasms in Nf1 mutant mice.
Cancer Cell
; 8(4): 337-48, 2005 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-16226708
12.
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.
Clin Lung Cancer
; 24(3): 218-227, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36890020
13.
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Target Oncol
; 18(1): 105-118, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36459255
14.
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
Clin Cancer Res
; 29(16): 3074-3080, 2023 08 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37279096
15.
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Target Oncol
; 17(2): 125-138, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35347559
16.
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
J Clin Oncol
; 40(23): 2530-2538, 2022 08 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35167329
17.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Cancer Discov
; 10(1): 54-71, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31658955
18.
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Cancer Chemother Pharmacol
; 81(2): 355-364, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29238851
19.
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.
JCO Precis Oncol
; 6: e2100551, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35952324
20.
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Target Oncol
; 17(2): 139, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35380379